The estimated Net Worth of Raul R Rodriguez is at least $27.7 Million dollars as of 2 February 2024. Mr Rodriguez owns over 52,894 units of Rigel Pharmaceuticals stock worth over $26,415,078 and over the last 21 years he sold RIGL stock worth over $325,244. In addition, he makes $971,119 as Pres and CEO & Director at Rigel Pharmaceuticals.
Mr has made over 5 trades of the Rigel Pharmaceuticals stock since 2004, according to the Form 4 filled with the SEC. Most recently he sold 52,894 units of RIGL stock worth $60,299 on 2 February 2024.
The largest trade he's ever made was buying 1,000,000 units of Rigel Pharmaceuticals stock on 9 June 2022 worth over $690,000. On average, Mr trades about 27,233 units every 161 days since 2003. As of 2 February 2024 he still owns at least 2,036,629 units of Rigel Pharmaceuticals stock.
You can see the complete history of Mr Rodriguez stock trades at the bottom of the page.
Raul R. Rodriguez is the Pres, CEO & Director at Rigel Pharmaceuticals.
As the Pres and CEO & Director of Rigel Pharmaceuticals, the total compensation of Mr Rodriguez at Rigel Pharmaceuticals is $971,119. There are 1 executives at Rigel Pharmaceuticals getting paid more, with David A. Santos having the highest compensation of $1,034,977.
Mr Rodriguez is 60, he's been the Pres and CEO & Director of Rigel Pharmaceuticals since . There are no older and 6 younger executives at Rigel Pharmaceuticals.
Raul's mailing address filed with the SEC is RIGEL PHARMACEUTICALS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 21 years, insiders at Rigel Pharmaceuticals have traded over $170,041,384 worth of Rigel Pharmaceuticals stock and bought 2,068,700 units worth $7,281,949 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Ansbert Gadicke, and Partners L P/Ilbiotechnolog.... On average, Rigel Pharmaceuticals executives and independent directors trade stock every 46 days with the average trade being worth of $961,207. The most recent stock trade was executed by David A Santos on 2 February 2024, trading 14,519 units of RIGL stock currently worth $16,552.
rigel pharmaceuticals, inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases.
Rigel Pharmaceuticals executives and other stock owners filed with the SEC include: